How to turn patent data into competitive advantage — from prior art to pipeline defense to biosimilar market entry Why […]

A deep-dive reference for pharma/biotech IP teams, R&D leads, portfolio managers, and institutional investors who need forecasts that hold up

A deep-dive reference for pharma IP counsel, portfolio managers, R&D leads, and institutional investors who need to turn litigation data

Key Takeaways (Executive Summary) Part 1: The Compounding Regulatory Architecture The Market Context The U.S. compounding pharmacy sector is not

Key Takeaways (Executive Summary) Part I: The R&D Productivity Crisis and the AI Imperative The Economics Are Broken The math

How to convert raw patent filings into predictive R&D roadmaps that de-risk pipelines, price M&A targets, and identify white space

The complete operational guide for pharma IP teams, portfolio managers, and supply chain leads on converting patent intelligence into production

Part I: The $15 Billion Paradox — A Market That Grows With the Brake On The pharmaceutical excipients market is

Every day a blockbuster drug holds patent protection is worth, on average, $8.2 million in revenue. That figure makes the